In a phase II study (NCT02337491) involving 80 patients with recurrent GBM who had not previously received bevacizumab, the PD-1 inhibitor pembrolizumab combined with bevacizumab demonstrated a 6-month PFS of 26.0%, a median OS of 8.8 months and an objective response rate (ORR) of 20%. The gene discussed is PDCD1; the disease is glioblastoma.